<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928419</url>
  </required_header>
  <id_info>
    <org_study_id>QOL-ONE Rev2MDS</org_study_id>
    <nct_id>NCT02928419</nct_id>
  </id_info>
  <brief_title>Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q</brief_title>
  <official_title>Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q: a Multicenter, Randomized, Double-blind, Placebo Controlled Study - QOL-ONE Rev2MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associazione Qol-one</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Associazione Qol-one</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myelodysplastic syndromes (MDS) prevail in elderly patients and are characterized by
      inefficient erythropoiesis and peripheral cytopenias. Supportive care still represents the
      main therapeutic option in most patients. Quality of life is deteriorated mostly by anemia
      and by limitations due to dependence on transfusions, thrombocytopenia, and neutropenia. The
      only treatment available for severe thrombocytopenia consists of PLT transfusions, mainly in
      the presence of bleeding.

      In patients with low and intermediate-1 risk MDS with an isolated deletion 5q cytogenetic
      abnormality, red blood cell (RBC) transfusion-dependence is a prevalent condition. For these
      latter patients reaching transfusion-dependence, lenalidomide, an immunomodulatory drug, has
      been approved by FDA and EMA. It has been shown that the drug induces significant erythroid
      (about 65%) and cytogenetic responses which have been associated with a survival benefit. In
      patients with MDS with del5q and serum erythropoietin levels &gt; 500 miU/L, lenalidomide dosing
      of 10 mg/day for 21 days every 28, rather than 5 mg dosing, induces higher rates of
      transfusion-independence and cytogenetic responses with a trend to survival advantage. As a
      consequence, the recommended starting dose of lenalidomide is 10 mg orally once daily on days
      1-21 of repeated 28-day cycles. Lenalidomide treatment must not be started if the Absolute
      Neutrophil Counts (ANC) &lt; 0.5 Gi/L and/or PLT counts &lt; 25 Gi/L.

      For patients who are dosed initially at 10 mg and who experience thrombocytopenia &lt; 25 Gi/L
      (45-75%), it is recommended to interrupt lenalidomide treatment until PLT count returns to ≥
      25 Gi/L on at least 2 occasions for ≥ 7 days or when the PLT count recovers to ≥ 50 Gi/L at
      any time, to resume lenalidomide at 50% dose reduction.

      Eltrombopag is an orally bioavailable agonist of the thrombopoietin receptor. It has been
      shown that in patients affected by MDS and by acute myeloid leukemia, Eltrombopag neither
      increases the proliferation, nor the clonogenic growth capacity of bone marrow blasts.
      Furthermore, Eltrombopag induces an increase in the megakaryocytic differentiation and in the
      formation of normal megakaryocytic colonies. These results provide the rationale for pursuing
      further research on Eltrombopag for the treatment of thrombocytopenia in case of MDS.

      Preliminary results of an ongoing randomized trial, EQoL-MDS, for the evaluation of efficacy,
      safety of eltrombopag for thrombocytopenia of low and intermediate-1 IPSS risk MDS has shown
      that eltrombopag is able to significantly raise PLT counts in about 65% of patients without
      additional toxicity Furthermore, the combination of lenalidomide and eltrombopag resulted in
      significant inhibitory effects on the growth of leukemic colonies in the majority of primary
      MDS and AML samples. Most importantly, eltrombopag was able to reverse the
      anti-megakaryopoietic effects of lenalidomide in primary MDS patient samples. These results
      provide a preclinical rationale for the use of this combination in MDS and AML
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response (patients number with composite endpoint experience)</measure>
    <time_frame>24 weeks</time_frame>
    <description>To evaluate the effect of eltrombopag treatment relative to placebo on the incidence of the &quot;composite endpoint&quot; (PLT&lt;25 Gi/L or bleeding event with WHO bleeding score &gt;1 or study discontinuation), in the first 24 weeks, after experiencing PLT&lt;100 Gi/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response (patients number with composite endpoint experience on long-term)</measure>
    <time_frame>36 months</time_frame>
    <description>The composite endpoint during the entire study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (number of adverse events)</measure>
    <time_frame>36 months</time_frame>
    <description>Safety and tolerability in terms of frequency of adverse events (AE)s and serious adverse events (SAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic responses</measure>
    <time_frame>36 months</time_frame>
    <description>Proportion of cytogenetic responses, according to IWG 2006 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of cytogenetic response</measure>
    <time_frame>36 months</time_frame>
    <description>Duration of cytogenetic response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb changes</measure>
    <time_frame>24 weeks</time_frame>
    <description>Hb changes within the first 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythroid response</measure>
    <time_frame>36 months</time_frame>
    <description>Erythroid response, transfusion-independence (TI) and duration of TI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL)</measure>
    <time_frame>36 months</time_frame>
    <description>Changes in QOL scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>36 months</time_frame>
    <description>Progression free survival from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm 1 (Eltrombopag)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 is the active treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2 is the control arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag/Revolade</intervention_name>
    <description>From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.
Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts &lt; 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted.</description>
    <arm_group_label>Arm 1 (Eltrombopag)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.
Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts &lt; 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted.</description>
    <arm_group_label>Arm 2 (Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation</description>
    <arm_group_label>Arm 1 (Eltrombopag)</arm_group_label>
    <arm_group_label>Arm 2 (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (18 years of age or older) with MDS and low or intermediate-1 IPSS risk
             and del5q as a single abnormality, at the time of their screening and enrollment into
             the study

          -  Subjects must not have received any prior treatment course with any immunomodulating
             agent nor TPO-R agonists

          -  Subjects must be dependent on regular packed RBC transfusions, as defined by
             international working group 2006 criteria, and must have a PLT count taken within the
             4 weeks prior to screening that is &gt;25 Gi/L.

          -  Absolute Neutrophil Counts (ANC) ≥ 0.5 GiL

          -  Resistant or refractory to erythropoetic stimulating agents (ESAs) and/or serum
             erythropoetin levels &gt; 500 miU/L

          -  Subjects must be ineligible or relapsed or refractory to receive treatment options of
             azacitidine and decitabine.

          -  Subjects must have PLT count and RBC and PLT transfusion data available over a period
             of 8 weeks prior to screening.

          -  During the 2 months prior to randomization, subjects must have a baseline BM
             examination including all of the following: cytomorphology, cytogenetics and histology

          -  ECOG Performance Status must be 0-3.

          -  The following clinical chemistries MUST NOT exceed the upper limit of normal (ULN)
             reference range: creatinine, ALT, AST, total bilirubin (except for Gilbert's
             Syndrome), gamma-gt and alkaline phosphatase. In addition, albumin must not be below
             the lower limit of normal (LLN) by more than 10%.

          -  If subject meets the criteria for childbearing potential:

               1. Negative pregnancy test in female subjects within the 3 days prior to Day 1 of
                  1st cycle and effective contraception for at least 4 weeks.

               2. Subject is practicing an acceptable method of contraception (documented in
                  chart). Female subjects (or female partners of male subjects) must either be of
                  non-childbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal
                  ligation or post-menopausal &gt;1 year), or of childbearing potential and use of an
                  highly effective method of contraception from 2 weeks prior to administration of
                  study medication, throughout the study, and 28 days after completion or premature
                  discontinuation from the study.

          -  Criteria for women of non-childbearing potential: A female patient or a female partner
             of a male patient is considered to have childbearing potential unless she meets at
             least one of the following criteria:

               1. Age ≥ 50 years and naturally amenorrhoeic for ≥ 1 year (amenorrhoea following
                  cancer therapy or during lactation does not rule out childbearing potential).

               2. Premature ovarian failure confirmed by a gynaecologist

               3. Previous bilateral salpingo-oophorectomy, or hysterectomy

               4. XY genotype, Turner syndrome, uterine agenesis.

          -  Subject is able to understand and comply with protocol requirements and instructions.

          -  Subject has signed and dated informed consent.

        Exclusion Criteria:

          -  MDS with intermediate-2 or high IPSS risk

          -  Additional cytogenetic abnormalities

          -  Transfusion independence (TI) by IWG 2006 criteria

          -  Absolute Neutrophil Count &lt; 0.5 Gi/L and/or Platelet counts &lt; 25 Gi/L

          -  History of treatment for cancer with systemic chemotherapy and/or radiotherapy within
             the last 2 years

          -  History of treatment with immunomodulatory drugs or other TPO-R agonists.

          -  Thrombophilia, pre-existing history of thrombosis, cardiovascular disease (including
             congestive heart failure, New York Heart Association [NYHA] Grade III/IV), or
             arrhythmia known to increase the risk of thromboembolic events (e.g. atrial
             fibrillation), or subjects with a QTc &gt;450 msec (QTc &gt;480 msec for subjects with
             Bundle Branch Block)

          -  Bone Marrow fibrosis that leads to an inability to aspirate marrow for assessment.

          -  Leukocytosis &gt;=25,000/uL prior to Day 1 of study medication.

          -  Monocytosis &gt; 1000/ uL prior to Day 1 of study medication.

          -  Female subjects who are nursing or pregnant (positive serum or urine Beta-human
             chorionic gonadotropin [B-hCG] pregnancy test).

          -  Women of childbearing potential unless all of the conditions of the Pregnancy
             Prevention Programme illustrated in sections 6.4 are met (see sections 6.4).

          -  Known hypersensitivity to lenalidomide.

          -  Current alcohol or drug abuse.

          -  Treatment with an Investigational Product within 30 days or 5 half-lives (whichever is
             longer) preceding the first dose of study medication.

          -  Active and uncontrolled infections.

          -  Subjects infected with Hepatitis B, C or Human Immunodeficiency Virus (HIV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Natalie Oliva, MD</last_name>
    <role>Study Chair</role>
    <affiliation>QOL-ONE Associazione Culturale e di Ricerca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esther Natalie Oliva, MD</last_name>
    <phone>+39 3298699514</phone>
    <email>qolone@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe Iannì</last_name>
    <phone>+39 3336589725</phone>
    <email>ianni@dielnet.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathilde Hunault</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Toma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Park</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamel Laribi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique Bordessoule</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Wattel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert Vey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agnes Guerci-Bresler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Delaunay</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Archet 1</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Legros</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nimes</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Jourdan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Rouen, Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aspasia Stamatoullas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Odile Beyne-Rauzy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Gyan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <state>AL</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Flavia Salvi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Riuniti</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonella Poloni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardinal Massaia</name>
      <address>
        <city>Asti</city>
        <state>AT</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monia Marchetti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. S. Giovanni Moscati</name>
      <address>
        <city>Avellino</city>
        <state>AV</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Volpe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Oncologico Businco</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emanuele Angelucci</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale L'Annunziata</name>
      <address>
        <city>Cosenza</city>
        <state>CS</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fortunato Morabito</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Di Raimondo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Garibaldi</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefana Impera</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valeria Santini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorenza Borin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agostino Cortelezzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Spirito Santo</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Di Bartolomeo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Bianchi-Melacrino-Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Oliva</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arcispedale di Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>A.O. San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Mancini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Eugenio</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pasquale Niscola</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luana Fianchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Andrea</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Antonietta Aloe Spiriti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Regina Elena</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Atelda Romano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Nuova Regina Margherita</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Andriani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuliana Alimena</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Tor Vergata</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Buccisano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Santa Maria alle Scotte</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monica Bocchia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria</name>
      <address>
        <city>Terni</city>
        <state>TE</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Citta' della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dario Ferrero</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Citta' della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernardino Allione</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

